Literature DB >> 12010770

Physiological antagonism between ventricular beta 1-adrenoceptors and alpha 1-adrenoceptors but no evidence for beta 2- and beta 3-adrenoceptor function in murine heart.

Jürgen F Heubach1, Thomas Rau, Thomas Eschenhagen, Ursula Ravens, Alberto J Kaumann.   

Abstract

1. Murine left atrium lacks inotropic beta(2)-adrenoceptor function. We investigated whether beta(2)-adrenoceptors are involved in the cardiostimulant effects of (-)-adrenaline on spontaneously beating right atria and paced right ventricular myocardium of C57BL6 mice. We also studied a negative inotropic effect of (-)-adrenaline. 2. Sinoatrial tachycardia, evoked by (-)-adrenaline was resistant to blockade by beta(2)-selective ICI 118,551 (50 nM) but antagonized by beta(1)-selective CGP 20712A (300 nM). This pattern was unaffected by pretreatment with pertussis toxin (PTX, 600 microg kg(-1) i.p. 24 h) which reversed carbachol-evoked bradycardia to tachycardia. 3. Increases of ventricular force by (-)-adrenaline and (-)-noradrenaline were not blocked by ICI 118,551 but antagonized by CGP 20712A. 4. Under blockade of beta-adrenoceptors, (-)-adrenaline and (-)-noradrenaline depressed ventricular force (-logIC(50)M=7.7 and 6.9). The cardiodepressant effects of (-)-adrenaline were antagonized by phentolamine (1 microM) and prazosin (1 microM) but not by (-)-bupranolol (1 microM). Prazosin potentiated the positive inotropic effects of (-)-adrenaline (in the absence of beta-blockers) from -logEC(50)M=6.2 - 6.8. 5. PTX-treatment reduced carbachol-evoked depression of ventricular force in the presence of high catecholamine concentrations. Inhibition of ventricular function of G(i) protein was verified by 82% reduction of in vitro ADP-ribosylation. PTX-treatment tended to increase the positive inotropic potency of (-)-adrenaline under all conditions investigated, including the presence of ICI 118,551. 6. (-)-Adrenaline causes murine cardiostimulation through beta(1)-adrenoceptors but not through beta(2)-adrenoceptors. The negative inotropic effects of (-)-adrenaline are mediated through ventricular alpha(1)-adrenoceptors but not through beta(3)-adrenoceptors. Both G(i) protein and alpha(1)-adrenoceptors restrain (-)-adrenaline-evoked increases in right ventricular force mediated through beta(1)-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010770      PMCID: PMC1573340          DOI: 10.1038/sj.bjp.0704700

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  56 in total

Review 1.  Proposal for the interaction of non-conventional partial agonists and catecholamines with the 'putative beta 4-adrenoceptor' in mammalian heart.

Authors:  P Molenaar; D Sarsero; A J Kaumann
Journal:  Clin Exp Pharmacol Physiol       Date:  1997 Sep-Oct       Impact factor: 2.557

2.  Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium.

Authors:  Martin D Lowe; James A Lynham; Andrew A Grace; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

3.  Pertussis toxin inhibits negative inotropic and negative chronotropic muscarinic cholinergic effects on the heart.

Authors:  S Tucek; V Dolezal; J Folbergrová; S Hynie; F Kolár; B Ostádal
Journal:  Pflugers Arch       Date:  1987-02       Impact factor: 3.657

4.  CGP 20712 A: a useful tool for quantitating beta 1- and beta 2-adrenoceptors.

Authors:  D J Dooley; H Bittiger; N C Reymann
Journal:  Eur J Pharmacol       Date:  1986-10-14       Impact factor: 4.432

5.  The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551).

Authors:  A J Bilski; S E Halliday; J D Fitzgerald; J L Wale
Journal:  J Cardiovasc Pharmacol       Date:  1983 May-Jun       Impact factor: 3.105

6.  Inhibition of sympathomimetic effects on the cardiovascular system by 4-(2-isopropylamino-1-hydroxyethyl)methanesulfonanilide hydrochloride (MJ 1999).

Authors:  P Aramendía; A J Kaumann
Journal:  J Pharmacol Exp Ther       Date:  1967-02       Impact factor: 4.030

7.  Demonstration of an alpha adrenoceptor-mediated inotropic effect of norepinephrine in human atria.

Authors:  T Skomedal; H Aass; J B Osnes; N B Fjeld; G Klingen; A Langslet; G Semb
Journal:  J Pharmacol Exp Ther       Date:  1985-05       Impact factor: 4.030

8.  An analysis of cholinergic involvement in postvagal tachycardia.

Authors:  J M Loeb; M Vassalle
Journal:  Cardiology       Date:  1978       Impact factor: 1.869

9.  The affinity of (-)-propranolol for beta 1- and beta 2-adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline.

Authors:  E Gille; H Lemoine; B Ehle; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

10.  The beta 1-adrenoceptor antagonist CGP 20712 A unmasks beta 2-adrenoceptors activated by (-)-adrenaline in rat sinoatrial node.

Authors:  A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-04       Impact factor: 3.000

View more
  13 in total

Review 1.  Cardiac β3 -adrenoceptors-A role in human pathophysiology?

Authors:  Ebru Arioglu-Inan; Gizem Kayki-Mutlu; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-22       Impact factor: 8.739

2.  Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats.

Authors:  Alberto J Kaumann; Alejandro Galindo-Tovar; Elisa Escudero; María Luisa Vargas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-20       Impact factor: 3.000

3.  beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current.

Authors:  V Arvydas Skeberdis; Vida Gendviliene; Danguole Zablockaite; Rimantas Treinys; Regina Macianskiene; Andrius Bogdelis; Jonas Jurevicius; Rodolphe Fischmeister
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

4.  Cardiostimulant and cardiodepressant effects through overexpressed human beta2-adrenoceptors in murine heart: regional differences and functional role of beta1-adrenoceptors.

Authors:  Jürgen F Heubach; Marianne Blaschke; Sian E Harding; Ursula Ravens; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-03-04       Impact factor: 3.000

5.  Inotropy and L-type Ca2+ current, activated by beta1- and beta2-adrenoceptors, are differently controlled by phosphodiesterases 3 and 4 in rat heart.

Authors:  Torsten Christ; Alejandro Galindo-Tovar; Marcus Thoms; Ursula Ravens; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

6.  Non-classical regulation of β1- and β 2-adrenoceptor-mediated inotropic responses in rat heart ventricle by the G protein Gi.

Authors:  Caroline Bull Melsom; Rizwan Iqbal Hussain; Øivind Ørstavik; Jan Magnus Aronsen; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Kurt Allen Krobert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-09-13       Impact factor: 3.000

Review 7.  Takotsubo cardiomyopathy.

Authors:  Tatsuji Kono; Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2014-09       Impact factor: 4.214

8.  Phosphodiesterase-4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (-)-adrenaline mediated through mouse cardiac beta(1)-adrenoceptors.

Authors:  A Galindo-Tovar; A J Kaumann
Journal:  Br J Pharmacol       Date:  2007-12-17       Impact factor: 8.739

9.  GPR55 deletion in mice leads to age-related ventricular dysfunction and impaired adrenoceptor-mediated inotropic responses.

Authors:  Sarah K Walsh; Emma E Hector; Anne-Christine Andréasson; Ann-Cathrine Jönsson-Rylander; Cherry L Wainwright
Journal:  PLoS One       Date:  2014-10-02       Impact factor: 3.240

Review 10.  The influence of diabetes on cardiac beta-adrenoceptor subtypes.

Authors:  V Melih Altan; Ebru Arioglu; Sahika Guner; A Tanju Ozcelikay
Journal:  Heart Fail Rev       Date:  2007-03-16       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.